Trump's tax-and-spending bill passes Congress in major win for president
The 218-214 vote came after weeks of wrangling over the measure that Trump demanded be ready for his signature by Friday, the Independence Day holiday. Written by his Republican allies in Congress and unanimously rejected by Democrats, the bill traveled an uncertain road to passage that saw multiple all-night votes in the House and Senate and negotiations that lasted until the final hours before passage. Ultimately, Republicans who had objected to its cost and contents folded, and the bill passed with just two GOP defections: Thomas Massie, a rightwing Kentucky lawmaker, and Brian Fitzpatrick, who represents a Pennsylvania district that voted for Kamala Harris in last year's election.
'We've waited long enough, some of us have literally been up for days now, but this day – this day – is a hugely important one in the history of our nation,' the Republican House speaker, Mike Johnson, said, just before voting began.
'With one big, beautiful bill, we are going to make this country stronger, safer and more prosperous than ever before, and every American is going to benefit from that.'
The legislation is expected to speed up and expand Immigration and Customs Enforcement deportations, and will probably make Trump's longstanding desire for a wall along the border with Mexico a reality.
Related: How Trump's bill will supercharge mass deportations by funneling $170bn to Ice
It also strikes a blow against the US government's efforts to fight the climate crisis by phasing out tax incentives created under Joe Biden that were intended to spur investments in electric cars, wind and solar power and other green energy technologies.
The bill's centerpiece is a permanent extension of tax cuts made in 2017, during Trump's first term, as well as the creation of new, temporary exemptions for tips, overtime pay and car loan interest that the president promised voters during last year's campaign.
The government will lose trillions of dollars in revenue from those provisions, and to offset their costs, Republicans approved an array of cuts to Medicaid, the federal program providing health insurance coverage to poor and disabled Americans, and the Supplemental Nutrition Assistance Program (Snap).
Those changes are expected to cost millions of people their benefits, but the bill remains expensive, with the non-partisan Congressional Budget Office (CBO) saying it will add $3.3tn to the country's debt through 2034.
Massie explained his decision to vote against the bill in a post on X, writing that 'it will significantly increase U.S. budget deficits in the near term, negatively impacting all Americans through sustained inflation and high interest rates'.
Fitzpatrick issued a statement saying 'it was the Senate's amendments to Medicaid, in addition to several other Senate provisions, that altered the analysis' for his district and made him vote no.
Democrats blasted the proposal as 'one big, ugly bill' that dismantles anti-poverty programs to fund tax breaks for the wealthy. Analyses have shown that high earners benefited most from Trump's tax policies.
The Democratic House minority leader, Hakeem Jeffries, made a last-ditch effort to halt the bill's passage by delivering a floor speech that lasted eight hours and 44 minutes, the longest ever.
'This is extraordinary. This assault on everyday Americans, assault on children, veterans, seniors, people with disabilities. It's incredible to me, all of this in this one, big, ugly bill,' Jeffries said.
'Ripping food out of the mouths of vulnerable Americans – that's extraordinary that that's what we're doing, extraordinary. And all of this is being done, this unprecedented assault on everyday Americans, is being unleashed on the American people, Mr Speaker, on the most vulnerable among us, all of this is being done to provide massive tax breaks to billionaire donors. Shame on this institution. If this bill passes, that's not America. We're better than this.'
Trump has described the bill as crucial to the success of his second term, and congressional Republicans made its passage their top priority. It was a tall task – the GOP won small majorities in both the House and Senate in last November's election, and could afford no more than three defections in either chamber.
The party's lawmakers broadly support Trump but were divided on a host of other issues. There were lawmakers who wanted big spending cuts, rapid phase-outs of green energy incentives and an expanded deduction that would mostly benefit taxpayers in Democratic-led states. Their demands butted against others who sought to moderate the bill, but over the course of weeks, Republicans leaders managed to forge a compromise.
Trump appears to have also offered some concessions to hard-line holdouts from the Republican House freedom caucus at a meeting at the White House on Wednesday and in subsequent discussions, as his advisers rushed to ensure the bill passed without returning to the Senate.
The details of Trump's concessions – possibly coming in the form of executive actions at a later date – were not immediately clear, and House freedom caucus chair Andy Harris declined to describe their discussions with Trump.
'When we looked at this entire package, the significant agreements we got with the administration in the last 24 hours made this package a much, much better package,' Harris told reporters after the vote. 'The agreement is with the president. If you want to know, ask the president.'
The bill is only able to affect revenue, spending and the debt limit, under the rules of budget reconciliation that allowed the GOP to avoid a filibuster by Democrats in the Senate. Under Biden, Congress's then Democratic majority had used the same procedure to pass legislation to spur the economy's recovery from the Covid-19 pandemic and curb US carbon emissions.
Related: What's in Trump's major tax bill? Extended cuts, deportations and more
Trump's bill allocates $45bn for Ice detention facilities, $14bn for deportation operations and billions of dollars more to hire 10,000 new agents by 2029. An additional $50bn will go towards the border wall and other fortifications.
Enrollees of Medicaid and Snap will face new work requirements, and states will be forced to share part of the cost of the latter program for the first time ever. The CBO estimates the bill's Medicaid changes could cost as many as 11.8 million people their healthcare, and the left-leaning Center on Budget and Policy Priorities forecasts about 8 million people, or one in five recipients, may lose their Snap benefits.
The legislation also forces changes to provider taxes, which states use to finance their share of Medicaid spending. That is expected to further increase the financial stress of hospitals in rural areas, and when the bill was in the Senate, a $50bn fund was added to support those facilities.
Some in the GOP were openly nervous about the cuts to safety net programs that their constituents rely on. Thom Tillis, a senator who represents swing state North Carolina, refused to support the bill for those reasons, leading Trump to announce he would support a primary challenger when he stands for re-election next year. Tillis then made public his plans to retire, a potential boost for Democrats' hopes of claiming his seat.
'It is inescapable this bill will betray the promise Donald Trump made,' Tillis said on the Senate floor.
'What do I tell 663,000 people in two years or three years when President Trump breaks his promise by pushing them off of Medicaid because the funding's not there any more, guys?'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Morgan Stanley Assumes Coverage of Axsome Therapeutics (AXSM) with an Overweight Rating
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 3, Morgan Stanley analyst Sean Laaman assumed coverage of Axsome Therapeutics, Inc. (NASDAQ:AXSM) with an Overweight rating and a $190 price target. The firm stated that the base case for the rating is the expected on-time supplemental New Drug application Submission for AXS-05 in Alzheimer's Disease Agitation. According to the analyst, it has a high probability of regulatory success and may lead to a potential $900 million in sales by 2030. A pharmacist preparing a prescription for a rapidly absorbed multi-mechanistic medicine. He further stated that the continued launch progress of Auvelity in major depressive disorder is another positive factor for Axsome Therapeutics, Inc. (NASDAQ:AXSM). The analyst told investors in a research note that this growth trajectory is anticipated to continue, supported by market penetration strategies and an expanded sales force. Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a commercial-stage biopharmaceutical company that develops and delivers therapies for central nervous system conditions with limited treatment options. Its two commercial products and development programs include Auvelity and Sunosi. Auvelity treats major depressive disorder (MDD), and Sunosi is an oral medication for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. While we acknowledge the potential of AXSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
30 minutes ago
- Yahoo
Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, Bloomberg News reported that AstraZeneca (NASDAQ:AZN) is in discussions with Summit Therapeutics for a licensing agreement concerning an experimental lung cancer drug, with a potential value of up to $15 billion. The proposed deal for the drug, which is known as ivonescimab, could involve an upfront payment of several billion dollars to Summit, in addition to future milestone payments. However, the talks are ongoing and could still fall apart. Summit might even choose to partner with a different company. Neither Summit nor AstraZeneca has officially commented on the report. A laboratory employee in a sterile environment inspecting a microscope focused on a Clostridioides difficile infection sample. Summit Therapeutics secured the rights to ivonescimab through a separate deal worth up to $5 billion with China-based Akeso in December 2022. Under that agreement, Summit gained exclusive rights to develop and commercialize ivonescimab in the US, Canada, Europe, and Japan, while Akeso (OTC:AKESF) retained rights for other regions, including China. The deal included an upfront payment of $500 million to Akeso and potential regulatory and commercial milestones of up to $4.5 billion. Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company that discovers, develops, and commercializes patient, physician, caregiver, and societal-friendly medicinal therapies. AstraZeneca (NASDAQ:AZN) is a biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines. While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
34 minutes ago
- Yahoo
Citizens JMP Reiterates a Buy Rating on Dynavax Technologies (DVAX) With a Price Target of $31
Dynavax Technologies Corporation (NASDAQ:DVAX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 23, Citizens JMP analyst Roy Buchanan reiterated a Buy rating on Dynavax Technologies Corporation (NASDAQ:DVAX) and set a price target of $31.00. A biopharmaceutical company executive signing a collaboration agreement with a partner. The company reported record net product revenue for HEPLISAV-B in fiscal Q1 2025, reaching $65 million and showing a 36% year-over-year growth. HEPLISAV-B is the first and only adult vaccine for hepatitis B approved in the US, the UK, and the EU. Its total estimated market share in the US rose to around 43%, compared to around 41% in fiscal Q1 2024. Dynavax Technologies Corporation (NASDAQ:DVAX) also announced plans for the new pandemic influenza adjuvant program and Lyme disease vaccine programs to enter clinical development in 2025 and 2027, respectively. In addition, the company expects top-line results in Part 1 of the Phase 1/2 shingles vaccine trial by fiscal Q3 2025. Dynavax Technologies Corporation (NASDAQ:DVAX) is a biopharmaceutical company that discovers, develops, and commercializes novel vaccines and immuno-oncology therapeutics. The company's product pipeline includes HEPLISAV-B, a vaccine for all known subtypes of the hepatitis B virus in adults aged 18 and above. While we acknowledge the potential of DVAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.